Liver transplant in patients with hepatocellular carcinoma;Trasplante hepático en pacientes con carcinoma hepatocelular

Cirugia Espanola

Volumn 84, Issue 3, 2008, Pages 117-124

  Moya Herráiz, Ángel ^a   Torres Quevedoa, Rodrigo ^a,b   Mir Pallardóa, José ^a  

^a HOSPITAL UNIVERSITARIO LA FE   (Spain)

^b UNIVERSITY OF CONCEPCIÓN   (Chile)

Author keywords

Diagnosis; Hepatocellular carcinoma; Liver cirrhosis; Liver transplantation; Percutaneous ablation; Transarterial chemoembolisation; Treatment

Indexed keywords

EID: 51849115938     PISSN: 0009739X     EISSN: 1578147X     Source Type: Journal    
DOI: 10.1016/S0009-739X(08)72152-3     Document Type: Review

References (67)

1. Martínez FJ. Epidemiología y etiología del hepatocarcinoma. Rev Esp Eferm Digest. 1994;86:665-71.
2. Suárez MA, Leiva MC, Santoyo J, et al. Detección de lesiones neoplásicas en pacientes cirróticos candidatos a trasplante hepático. Cir Esp. 2006;80:157-61.
3. Fattovich G, Stroffolini T, Zagni I, Donato F. Hepatocellular carcinoma in cirrhosis: incidence and risk factors. Gastroenterol. 2004;127 Suppl I:S35-50.
4. Starzl TE, Putnam CW. Experience in hepatic transplantation. Philadelphia: WB Saunders; 1969. p. 350-73.
5. Pichlmayr R. Is there a place for liver grafting for malignancy? Transplant Proc. 1988;20 Suppl 1:478-82.
6. Penn I. Hepatic transplantation for primary and metastatic cancers of the liver. Surgery. 1991;110:726-35.
7. Iwatsuki S, Gordon RD, Shaw BW Jr, Starzl TE. Role of liver transplantation in cancer therapy. Ann Surg. 1985;202:401-7.
8. Bismuth H, Chiche L, Adam R, Castaing D, Diamond T, Dennison A. Liver resection versus transplantation for hepatocellular carcinoma in cirrhotic patients. Ann Surg. 1993;218:145-51.
9. Mazzaferro V, Regalia E, Doci R, Andreola S, Pulvirenti A, Bozzetti F, et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med. 1996;334:693-9.
10. Figueras J, Jaurrieta E, Valls C, Benasco C, Rafecas A, Xiol X, et al. Survival after liver transplantation in cirrhotic patients with and without hepatocellular carcinoma: a comparative study. Hepatology. 1997;25:1485-9.
11. Murray KF, Carithers RI Jr. AASLD Practice guidelines: evaluation of the patient for liver transplantation. Hepatology. 2005;41:1-26.
12. Bolondi L, Sofia S, Siringo S, Gaiani S, Casali A, Zironi G, et al. Surveillace programme of cirrhotic patients for early diagnosis and treatment of hepatocellular carcinoma: a cost-effectiveness analysis. Gut. 2001;48:251-9.
13. Bruix J, Sherman M. Management of hepatocellular carcinoma. Hepatology. 2005;42:1208-36.
14. Trevisani F, D'Intino PE, Morselli-Labate AM, Mazzella G, Accogli E, Caraceni P, et al. Serum alpha-fetoprotein for diagnosis of hepatocellular carcinoma in patients with chronic liver disease: influence of HBsAg and anti-HCV status. J Hepatol. 2001;34:570-5.
15. Oka H, Tamori A, Kuroki T, Kobayashi K, Yamamoto S. Prospective study of alpha-protein in cirrhotic patients monitored for development of hepatocellular carcinoma. Hepatology. 1994;19:61-6.
16. Llovet JM, Bustamante J, Castells A, Vilana R, Ayuso MC, Sala M, et al. Natural history of untreated nonsurgical hepatocellular carcinoma: rationale for the design and evaluation of therapeutic trials. Hepatology. 1999;29:62-7.
17. Bruix J, Sherman M, Llovet JM, Beaugrand M, Lencioni R, Burroughs AK, et al. Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. J Hepatol. 2001;35:421-30.
18. Yao FY, Ferrell L, Bass NM, Watson JJ, Bachetti P, Venook A, et al. Liver transplantation for hepatocellular carcinoma: expansion of the tumor size limits does not advesely impact survival. Hepatology. 2001;33:1394-403.
19. Shetty K, Timmins K, Brensinger C, Furth EE, Rattan S, Sun W, et al. Liver transplantation for hepatocellular carcinoma validation of present selection criteria in predicting outcome. Liver Transpl. 2004;10:911-8.
20. Onaca N, Davis GL, Goldstein RM, Jennings LW, Klintmalm GB. Expanded criteria for liver transplantation in patients with hepatocellular carcinoma: a report from the international registry of hepatic tumors in liver transplantation. Liver Transpl. 2007;13:391-9.
21. Llovet JM, Bruix J, Fuster J, Castells A, Garcia-Valdecasas JC, Grande L, et al. Liver transplantation for small hepatocellular carcinoma: the tumor-node-metastasis classification does not have prognostic power. Hepatology. 1998;27:1572-7.
22. Fleming ID. AJCC/TNM cancer staging, present and future. J Surg Oncol. 2001;77:233-6.
23. Vauthey JN, Lauwers GY, Esnaola NF, Do KA, Belghiti J, Mirza N, et al. Simplified staging for hepatocellular carcinoma. J Clin Oncol. 2002;20:1527-36.
24. Llovet JM, Bru C, Bruix J. Prognosis of hepatocellular carcinoma: the BCLC stanging classification. Semin Liver Dis. 1999;19:329-38.
25. Marrero JA, Fontana RJ, Barrat A, Askari F, Conjeevaram HS, Su GL, et al. Prognosis of hepatocellular carcinoma: comparison of 7 stanging systems in an American cohort. Hepatology. 2005;41:707-16.
26. Grieco A, Pompili M, Caminiti G, Miele L, Comino M, Alfei B, et al. Prognostic factors for survival in patients with early-intermediate hepatocellular carcinoma undergoing non-surgical therapy: comparison of Okuda, CLIP and BCLC stanging systems in a single Italian centre. Gut. 2005;54:411-8.
27. Wiesner RH, McDiarmid SV, Kamath PS, Edwards EB, Malinchoc M, Kremer WK, et al. MELD and PELD: application of survival models to liver allocation. Liver Transpl. 2001;7:567-80.
28. Wiesner RH, Edwards EB, Freeman R, Harper A, Kim R, Kamath PS, et al. And the United Network for Organ Sharing Liver Disease severity score committee. Model for end-stage liver disease (MELD) and allocation of donor livers. Gastroenterol. 2003;124:91-6.
29. United Network for Organ Sharing. Policy 3.6 [citado 19 Sep 2003]. Disponible en: http://www.unos.org
30. Freeman FB, Wiesner RH, Edwards EB, Harper A, Merion R, Wolfe R, et al. Results of first year of the new liver allocation plan. Liver Transpl. 2004;10:7-15.
31. Yao FY, Bass NM, Ascher NL, Roberts JP. Liver transplantation for hepatocellular carcinoma: lessons from the first year under the Model of End-Stage Liver Disease (MELD) Organ Allocation Policy. Liver Transpl. 2004;10:621-30.
32. Sala M, Llovet JM, Vilana R, Bianchi LL, Solé M, Ayuso C, et al. Initial response to percutaneous ablation predicts survival in patients with hepatocellular carcinoma. Hepatology. 2004;40:1352-60.
33. Shiina S, Teratani T, Obi S, Sato S, Tateishi R, Fujishima T, et al. A randomized controlled trial of radiofrequency ablation with ethanol injection for small hepatocellular carcinoma. Gastroenterol. 2005;129:122-30.
34. Lu DSK, Yu NC, Raman SS, Lassman C, Tong MJ, Britten C, et al. Percutaneous radiofrequency ablation of hepatocellular carcinoma as a bridge to liver transplantation. Hepatology. 2005;41:1130-7.
35. Llovet JM, Fuster J, Bruix J. Intention-to- treat analysis of surgical treatment for early hepatocellular carcinoma: resection versus transplantation. Hepatology. 1999;30:1434-40.
36. Figueras J, Valls C, Fabregat J, Serrano T, Jaurrieta E. Equipamiento, experiencia, mínima y estándares en la cirugía hepatobiliopancreática (HBP). Cir Esp. 2002;71:201-6.
37. Moya A, López R, San Juan F, Serralta A, De Juan M, Pareja E, et al. Patrones de calidad en el manejo del carcinoma hepatocelular mediante resección hepática: criterios de selección y resultados en una unidad de referencia de cirugía hepatobiliar. Cir Esp. 2004;76:101-6.
38. Minagawa M, Makuuchi M, Takayama T, Kokudo N. Selection criteria for repeat hepatectomy in patients with recurrent hepatocellular carcinoma. Ann Surg. 2003;238:703-10.
39. Imamura H, Matsuyama Y, Tanaka E, Ohkubo T, Hasegawa K, Miyagawa S, et al. Risk factors contributing to early and late phase intrahepatic recurrence of hepatocellular carcinoma after hepatectomy. J Hepatol. 2003;38:200-7.
40. Sarasin FP, Giostra E, Mentha G, Hadengue A. Partial hepatectomy or orthotopic liver transplantation for the treatment of resectable hepatocellular carcinoma? A cost-effectiveness perspective. Hepatology. 1998;28:436-42.
41. Jonas S, Bechstein WO, Steinmuller T, Herrmann M, Radke C, Berg T, et al. Vascular invasion and histopathologic grading determine outcome after liver transplantation for hepatocellular carcinoma in cirrhosis. Hepatology. 2001;33:1080-6.
42. Varela M, Sanchez W, Bruix J, Gores GJ. Hepatocellular carcinoma in the setting of liver transplantation. Liver Transpl. 2006;12:1028-36.
43. Marsh JW, Dvorchick I. Liver organ allocation for hepatocellular carcinoma: are we sure? Liver Transpl. 2003;9:693-6.
44. Bruix J, Fuster J, Llovet JM. Liver transplantation for hepatocellular carcinoma: Foucault pendulum versus evidence-based decision. Liver Transpl. 2003;9:700-2.
45. Roayaie S, Frischer JS, Emre SH, Fishbein TM, Sheiner PA, Sung M, et al. Logm-term results with multimodal adyuvant therapy and liver transplantation for the treatment of hepatocellular carcinomas larger than 5 centimeters. Ann Surg. 2002;235:533-9.
46. Fuster J, Charco R, Llovet JM, Garcia-Valdecasas JC. Liver transplantation in hepatocellular carcinoma. Transpl Int. 2005;18:278-82.
47. Yao FY, Bas NM, Nikolai B, Davern TJ, Kerlan R, Wu V, et al. Liver transplantation for hepatocellular carcinoma: analysis of survival accoding to the intention-to-treat principle and dropout from the waiting list. Liver Transpl. 2002;8:873-83.
48. Sarasin FP, Majno P, Llovet JM, Bruix J, Mentha J, Hadengue A. Living donor liver transplantation for early hepatocellular carcinoma: A life- expectancy and cost-effectiveness perspective. Hepatology. 2001;33:1073-9.
49. Llovet JM, Schwartz M, Fuster J, Bruix J. Expanded criteria for hepatocellular carcinoma through down-staging prior to liver transplantation: not yet there. Semin Liver Dis. 2006;26:248-53.
50. Graziadei IW, Sandmueller H, Waldenberger P, Koenigsrainer A, Nachbaur K, Jaschke W, et al. Chemoembolization followed by liver transplantation for hepatocellular carcinoma impedes tumor progression while on the waiting list and leads to excellent outcome. Liver Transpl. 2003;9:557-63.
51. Millonig G, Graziadei IW, Freund MC, Jaschke W, Stadlmann S, Ladurner R, et al. Response to preoperative chemoembolization correlates with outcome after liver transplantation in patients with hepatocellular carcinoma. Liver Transpl. 2007;13:272-9.
52. Bruix J, Sala M, Llovet JM. Chemoembolization for hepatocellular carcinoma. Gastroenterol. 2004;127 5 Suppl 1:S179-88.
53. Llovet JM, Bruix J. Systematic review of randomized trials for unresectable hepatocellular carcinoma: chemoembolization improves survival. Hepatology. 2003;37:429-42.
54. Llovet JM, Real MI, Maontanya X, Planas R, Coll S, Aponte AJ, et al. Arterial embolization, chemoembolization versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomized controlled trial. Lancet. 2002;359:1734-9.
55. Otto G, Herber SW, Helse M, Lohse AW, Mönch C, Bittinger F, et al. Response to transarterial chemoembolization as a biological selection criterion for liver transplanattion in hepatocellular carcinoma. Liver Transpl. 2006;12:1260-7.
56. Livraghi T, Solbiati L, Meloni MF, Gazelle GS, Halpern EF, Goldberg SN. Treatment of focal liver tumors with percutaneous radio-frequency ablation: complications encountered in a multicenter study. Radiology. 2003;226:441-51.
57. Majno P, Mentha G, Mazzaferro V. Resection, transplantation, either, or both? Other pieces of the puzzle. Liver Transpl. 2005;11:1177-80.
58. Majno P, Sarasin FP, Mentha G, Hadengue A. Primary liver resection and salvage transplantation or primary liver transplantation in patients with single, small hepatocellular carcinoma and preserved livers function: an outcome-oriented decision analysis. Hepatology. 2000;31:899-906.
59. Adam R, Azoulay D, Castaing D, Eshkenazy R, Pascal G, Hashizume K, et al. Liver resection as a bridge to transplantation for hepatocellular carcinoma on cirrhosis: a reasonable strategy? Ann Surg. 2003;238:508-19.
60. Belghiti J, Cortes A, Abdalla EK, Regimbeau JM, Prakash K, Durand F, et al. Resection prior to liver transplantation for hepatocellular carcinoma. Ann Surg. 2003;238:885-93.
61. Sala M, Fuster J, Llovet JM, Navasa M, Sole M, Varela M, et al. Barcelona Clinic Liver Cancer (BCLC) Group. High pathological risk of recurrence after surgical resection for hepatocellular carcinoma: a indication for salvage liver transplantation. Liver Transpl. 2004;10:1294-300.
62. Margarit C, Escartin A, Castells LL, Vargas V, Allende E, Bilbao I. Resection for hepatocellular carcinoma is a good option in Child-Turcotte-Pugh class A patients with cirrhosis who are eligible for liver transplantation. Liver Transpl. 2005;11:1242-51.
63. Sotiropoulos GC, Malagó M, Molmenti EP, Lösch C, Lang H, Frilling A, et al. Hilar lymph nodes sampling at the time of liver transplantation for hepatocellular carcinoma: to do or not to do? Transpl Int. 2007;20:141-6.
64. Zavaglia C, De Carlis L, Alberti AB, Minola E, Belli LS, Slim AO, et al. Predictors of long-term survival after liver transplantation for hepatocellular carcinoma. Am J Gastroenterol. 2005;100:2708-16.
65. Shimodas M, Ghobrial RM, Carmody IC, Anselmo DM, Farmer DG, Yersiz H, et al. Predictors of survival after liver transplantation for hepatocellular carcinoma associated with hepatitis C. Liver Transpl. 2004;10:1478-86.
66. Moya A, Berenguer M, Aguilera V, San Juan F, Nicolas D, Pastor M, et al. Hepatocellular carcinoma: can it be considered a controversial indication for liver transplantation in centres with high rates of hepatitis C. Liver Transpl. 2002;8:1020-7.
67. Rafecas A, Jaurrieta E, Figueras J. Tumores hepáticos. En: Trasplante hepático. Madrid: Joaquin Berenguer y Pascual Parrilla; 1999. p. 423-30.